Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Jonasch, E.
Bair, A.
Chen, Y.
Rini, B. I.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Pfizer Oncol, San Diego, CA USA
[3] Cleveland Clin, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps235
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS235
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era
    Numakura, Kazuyuki
    Muto, Yumin
    Naito, Sei
    Hatakeyama, Shingo
    Kato, Renpei
    Koguchi, Tomoyuki
    Kojima, Takahiro
    Kawasaki, Yoshihide
    Kandori, Syuya
    Kawamura, Sadafumi
    Arai, Yoichi
    Ito, Akihiro
    Nishiyama, Hiroyuki
    Kojima, Yoshiyuki
    Obara, Wataru
    Ohyama, Chikara
    Tsuchiya, Norihiko
    Habuchi, Tomonori
    [J]. CANCER MEDICINE, 2021, 10 (17): : 5839 - 5846
  • [42] An alternative titration schedule of axitinib in metastatic renal cell carcinoma
    Alva, Vyshak
    Wood, Laura S.
    Elson, Paul
    Martin, Allison
    Beach, Jennifer
    Garcia, Jorge A.
    Rini, Brian I.
    [J]. BJU INTERNATIONAL, 2014, 114 : 1 - 2
  • [43] An alternative titration schedule of axitinib in metastatic renal cell carcinoma
    Venur, Vyshak Alva
    Wood, Laura S.
    Elson, Paul
    Martin, Allison
    Beach, Jennifer
    Garcia, Jorge A.
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [44] Efficacy of first-line combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS).
    Carril, Lucia
    Colomba, Emeline
    Romero-Ferreiro, Carmen
    Cerbone, Luigi
    Ratta, Raffaele
    Barthelemy, Philippe
    Vindry, Clarisse
    Cherifi, Francois
    Boughalem, Elouen
    Linassier, Claude
    Fornarini, Giuseppe
    Gross-Goupil, Marine
    Saldana, Carolina
    Soberon, Maria Cruz Martin
    de Velasco, Guillermo
    Pernaut, Cristina
    Silva, Carolina Alves Costa
    Flippot, Ronan
    Escudier, Bernard
    Albiges, Laurence
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [45] First-line treatment of metastatic renal cell carcinoma
    Bruchbacher, Andreas
    Netsch, Christopher
    Gross, Andreas J. J.
    [J]. UROLOGIE, 2023, 62 (08): : 830 - 839
  • [46] Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).
    Bjarnason, Georg A.
    Knox, Jennifer J.
    Kollmannsberger, Christian K.
    Soulieres, Denis
    Ernst, D. Scott
    Canil, Christina M.
    Winquist, Eric
    Zalewski, Pawel
    Hotte, Sebastien J.
    North, Scott A.
    Heng, Daniel Yick Chin
    Macfarlane, Robyn Jane
    Venner, Peter M.
    Tannock, Ian
    Kapoor, Anil
    Eigl, Bernhard J.
    Hansen, Aaron Richard
    Czaykowski, Piotr
    Boyd, Ben
    Basappa, Naveen S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
    Escudier, Bernard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1176 - 1178
  • [48] The optimize project: beyond first-line therapy in metastatic renal cell carcinoma
    Castellano, Daniel
    Bellmunt, Joaquim
    [J]. CANCER AND METASTASIS REVIEWS, 2012, 31 : S1 - S2
  • [49] The optimize project: beyond first-line therapy in metastatic renal cell carcinoma
    Daniel Castellano
    Joaquim Bellmunt
    [J]. Cancer and Metastasis Reviews, 2012, 31 : 1 - 2
  • [50] PISCES: A Horoscope for First-Line Targeted Therapy of Metastatic Renal Cell Carcinoma
    Sun, Maxine
    Larcher, Alessandro
    Schiffmann, Jonas
    Karakiewicz, Pierre I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) : 3783 - +
12345